Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World... IntroductionA high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI.MethodsA retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date.ResultsThe cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively.ConclusionsIntensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/guideline-ldl-c-threshold-achievement-in-acute-myocardial-infarction-kC0mVHIW43
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2022. corrected publication 2023
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-022-00300-7
Publisher site
See Article on Publisher Site

Abstract

IntroductionA high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI.MethodsA retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date.ResultsThe cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively.ConclusionsIntensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes.

Journal

Cardiology and Therapy – Springer Journals

Published: Jan 19, 2023

Keywords: Proprotein convertase subtilisin/kexin type 9 inhibitors; Lipid-lowering therapy; Acute myocardial infarction; Low-density lipoprotein cholesterol; Real-world evidence

References

  • Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: a real-world evidence study
    Chen, G; Farris, MS; Cowling, T; Pinto, L; Rogoza, RM; MacKinnon, E
  • Lipid testing, lipid-modifying therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor eligibility in 27 979 patients with incident acute coronary syndrome
    Sarak, B; Savu, A; Kaul, P; McAlister, FA; Welsh, RC; Yan, AT
  • Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults
    Pearson, GJ; Thanassoulis, G; Anderson, TJ; Barry, AR; Couture, P; Dayan, N
  • Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention
    Sud, M; Han, L; Koh, M; Abdel-Qadir, H; Austin Peter, C; Farkouh Michael, E
  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
    Grundy, SM; Stone, NJ; Bailey, AL; Beam, C; Birtcher, KK; Blumenthal, RS
  • 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk
    Lloyd-Jones, DM; Morris, PB; Ballantyne, CM; Birtcher, KK; Covington, AM; DePalma, SM
  • 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
    Mach, F; Baigent, C; Catapano, AL; Koskinas, KC; Casula, M; Badimon, L
  • Evolocumab and clinical outcomes in patients with cardiovascular disease
    Sabatine, MS; Giugliano, RP; Keech, AC; Honarpour, N; Wiviott, SD; Murphy, SA
  • Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study
    Gaudet, D; López-Sendón, JL; Averna, M; Bigot, G; Banach, M; Letierce, A
  • Recent temporal changes in atherosclerotic cardiovascular diseases in Ontario: clinical and health systems impact
    Tu, JV; Khan, AM; Ng, K; Chu, A
  • Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
    Friedewald, WT; Levy, RI; Fredrickson, DS
  • A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
    Charlson, ME; Pompei, P; Ales, KL; MacKenzie, CR
  • Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
    Deyo, RA; Cherkin, DC; Ciol, MA
  • Measuring potentially avoidable hospital readmissions
    Halfon, P; Eggli, Y; van Melle, G; Chevalier, J; Wasserfallen, JB; Burnand, B
  • Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
    Quan, H; Sundararajan, V; Halfon, P; Fong, A; Burnand, B; Luthi, JC
  • Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US
    Cannon, CP; De Lemos, JA; Rosenson, RS; Ballantyne, CM; Liu, Y; Gao, Q
  • Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study
    Ray, KK; Dhalwani, N; Sibartie, M; Bridges, I; Ebenbichler, C; Perrone-Filardi, P
  • Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction
    McKinley, EC; Bittner, VA; Brown, TM; Chen, L; Colantonio, LD; Exter, J
  • Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction
    Gencer, B; Mach, F; Murphy, SA; De Ferrari, GM; Huber, K; Lewis, BS
  • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
    Baigent, C; Blackwell, L; Emberson, J; Holland, LE; Reith, C; Bhala, N
  • Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
    Giugliano, RP; Pedersen, TR; Park, JG; De Ferrari, GM; Gaciong, ZA; Ceska, R
  • Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial
    Murphy, SA; Cannon, CP; Blazing, MA; Giugliano, RP; White, JA; Lokhnygina, Y
  • Ezetimibe added to statin therapy after acute coronary syndromes
    Cannon, CP; Blazing, MA; Giugliano, RP; McCagg, A; White, JA; Theroux, P
  • Alirocumab and cardiovascular outcomes after acute coronary syndrome
    Schwartz, GG; Steg, PG; Szarek, M; Bhatt, DL; Bittner, VA; Diaz, R